Breaking Down Revenue Trends: Teva Pharmaceutical Industries Limited vs Sarepta Therapeutics, Inc.

Pharma Revenue Trends: Teva vs. Sarepta

__timestampSarepta Therapeutics, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 2014975700020272000000
Thursday, January 1, 2015125300019652000000
Friday, January 1, 2016542100021903000000
Sunday, January 1, 201715458400022385000000
Monday, January 1, 201830103400018854000000
Tuesday, January 1, 201938083300016887000000
Wednesday, January 1, 202054009900016658000000
Friday, January 1, 202170188700015878000000
Saturday, January 1, 202293301300014925000000
Sunday, January 1, 2023124333600015846000000
Monday, January 1, 202416544000000
Loading chart...

Unleashing insights

Revenue Trends in Pharmaceuticals: A Comparative Analysis

In the ever-evolving pharmaceutical industry, revenue trends offer a glimpse into the strategic maneuvers of key players. Teva Pharmaceutical Industries Limited, a giant in the generic drug market, has seen its revenue fluctuate over the past decade. From 2014 to 2023, Teva's revenue peaked in 2017, reaching approximately $22 billion, before experiencing a gradual decline to around $15.8 billion in 2023. This represents a 29% decrease, highlighting challenges in maintaining market dominance.

Conversely, Sarepta Therapeutics, Inc., a leader in genetic medicine, has demonstrated impressive growth. Starting with a modest revenue of under $10 million in 2014, Sarepta's revenue surged to over $1.2 billion by 2023, marking an exponential increase of over 12,000%. This growth underscores Sarepta's successful innovation and market expansion strategies. The contrasting trajectories of these companies reflect broader industry trends and strategic shifts.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025